Recent Updates
Recently added Catalysts
DNA Positive Sentiment

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ginkgo Bioworks has secured a subcontract worth up to $17.5 million from ARPA-H's GIVE program. This initiative focuses on developing a continuous-flow manufacturing system for RNA medicines. Ginkgo will collaborate with Waterfall Scientific to advance this transformative project, which aims to improve individualized medicine production.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ginkgo Bioworks awarded a significant subcontract of up to $17.5M.
  • The project aims to revolutionize RNA medicine manufacturing.
  • Collaboration with Waterfall Scientific enhances credibility and resources.

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a mul

Frequently Asked Questions

What is the purpose of the ARPA-H GIVE program?

The ARPA-H GIVE program aims to advance genetic medicines and individualized manufacturing.

How much funding did Ginkgo Bioworks receive?

Ginkgo Bioworks was awarded a subcontract for up to $17.5 million.

Who is Ginkgo Bioworks collaborating with?

Ginkgo is collaborating with Waterfall Scientific, Inc. on this project.

What is the ESCALATOR project?

The ESCALATOR project focuses on developing a continuous-flow manufacturing system for RNA medicines.

ShareAdd on Google
Tags: DNA Viatris Investor Conferences Healthcare Ginkgo Bioworks ARPA-H RNA medicines Waterfall Scientific biotechnology
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$172M liquidity · $15M/mo burn
~11 mo
Medium dilution risk